Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced the closing of its initial public offering of 4,545,455 shares of common stock at a public offering price of $11.00 per share for gross proceeds of $50.0 million before underwriting discounts and commissions.
In addition, the Company has granted the underwriters a 30-day option to purchase up to 681,818 additional shares of common stock at the initial public offering price, less the underwriting discount.
The Company’s common stock began trading on the Nasdaq Capital Market under the ticker symbol “LQDA” on July 26, 2018. All of the shares sold in the offering were offered by the Company.
Jefferies and Cowen acted as joint book-running managers for the offering. Needham & Company and Wedbush PacGrow acted as co-managers.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on July 25, 2018. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it.; or from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (631) 274-2806 or by fax at (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.